2-氟-4-羟基甲基苯甲腈 | 222978-02-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-氟-4-羟基甲基苯甲腈
• 中文别名: 4-氰基-3-氟苄醇
• 英文名称: 2-fluoro-4-(hydroxymethyl)benzonitrile
• CAS: 222978-02-1
• 化学式: C₈H₆FNO
• mdl: MFCD08236861
• 分子量: 151.14
• InChiKey: WLQHJQUGYACADR-UHFFFAOYSA-N

物化性质

• 熔点：
  66-68

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  44
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2926909090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302
• 储存条件：
  室温和干燥环境

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Fluoro-4-(hydroxymethyl)benzonitrile
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Fluoro-4-(hydroxymethyl)benzonitrile
CAS number: 222978-02-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H6FNO
Molecular weight: 151.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氟-4-羟基甲基苯甲腈 在 四磷十氧化物 、 sodium hydride 、 potassium bromide 作用下， 以 四氢呋喃 、 乙腈 为溶剂， 反应 1.0h， 生成 tert-butyl {(tert-butoxy)-N-[(4-cyano-3-fluorophenyl)methyl]carbonylamino}formate
  参考文献：
  名称：

  底物-模拟弗林蛋白酶抑制剂的优化

  摘要：

  前蛋白转化酶弗林蛋白酶是药物设计的潜在目标，尤其是对于抑制弗林蛋白酶依赖性病毒复制的抑制。到目前为止，鉴定出的所有有效的合成弗林蛋白酶抑制剂都是多元化合物。我们以前开发的抑制剂4-（胍基甲基）苯基乙酰基-Arg-Tle-Arg-4-ami基苄基酰胺（MI-1148）被发现具有最高的效价。小鼠的初步研究表明，该四元化合物的治疗范围狭窄，而某些三元类似物的毒性则大大降低。这表明毒性至少在某种程度上取决于该抑制剂的整体多元特性。因此，在第一种方法中，将MI-1148的C末端联苯胺替换为碱性较低的P1残基。尽管效力降低，但仍有少数化合物在低纳摩尔范围内抑制弗林蛋白酶，但在细胞中的功效微不足道。在第二种方法中，将P2精氨酸替换为赖氨酸。与MI-1148相比，这种弗林蛋白酶抑制剂的效力略有降低，但在细胞培养中对西尼罗河和登革热病毒表现出相似的抗病毒活性，在小鼠中的毒性也有所降低。这些结果为开发有效且耐

  DOI：

  10.1002/cmdc.201700596
• 作为产物：
  描述：

  2-氟-4-甲基苯腈 在 sodium tetrahydroborate 、 N-溴代丁二酰亚胺(NBS) 、 偶氮二异丁腈 、 silver nitrate 作用下， 以 四氯化碳 、 乙醇 为溶剂， 反应 27.17h， 生成 2-氟-4-羟基甲基苯甲腈
  参考文献：
  名称：

  3-Aminopyrrolidinone Farnesyltransferase Inhibitors:  Design of Macrocyclic Compounds with Improved Pharmacokinetics and Excellent Cell Potency

  摘要：

  A series of macrocyclic 3-aminopyrrolidinone farnesyltransferase inhibitors (FTIs) has been synthesized. Compared with previously described linear 3-aminopyrrolidinone FTIs such as compound 1, macrocycles such as 49 combined improved pharmacokinetic properties with a reduced potential for side effects. In dogs, oral bioavailability was good to excellent, and increases in plasma half-life were due to attenuated clearance. It was observed that in vivo clearance correlated with the flexibility of the molecules and this concept proved useful in the design of FTIs that exhibited low clearance, such as FTI 78. X-ray crystal structures of compounds 49 and 66 complexed with farnesyltransferase (FTase)-farnesyl diphosphate (FPP) were determined, and they provide details of the key interactions in such ternary complexes. Optimization of this 3-aminopyrrolidinone series of compounds led to significant increases in potency, providing 83 and 85, the most potent inhibitors of FTase in cells described to date.

  DOI：

  10.1021/jm010531d

文献信息

• Method of treating cancer
  申请人：——

  公开号：US20030220241A1

  公开（公告）日：2003-11-27

  The present invention relates to methods of treating cancer using a combination of a compound which is a PSA conjugate and a compound which is a inhibitor of prenyl-protein transferase, which methods comprise administering to said mammal, either sequentially in any order or simultaneously, amounts of at least two therapeutic agents selected from a group consisting of a compound which is a PSA conjugate and a compound which is a inhibitor of prenyl-protein transferase. The invention also relates to methods of preparing such compositions.

  本发明涉及使用一种PSA共轭物和一种前脂蛋白转移酶抑制剂的组合治疗癌症的方法，该方法包括向所述哺乳动物施用来自以下组中选择的至少两种治疗剂的量，所述组包括一种PSA共轭物和一种前脂蛋白转移酶抑制剂，所述治疗剂可以顺序给药或同时给药。该发明还涉及制备这种组合物的方法。
• Mandelic acid derivatives and their use as throbin inhibitors
  申请人：——

  公开号：US20040019033A1

  公开（公告）日：2004-01-29

  There is provided a compound of formula I 1 wherein R a , R 1 , R 2 , Y and R 3 have meanings given in the description and pharmaceutically acceptable derivatives (including prodrugs) thereof, which compounds and derivatives are useful as, or are useful as prodrugs of, competitive inhibitors of trypsin-like proteases, such as thrombin, and thus, in particular, in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants.

  提供了一种公式I的化合物 1 其中R a , R 1 , R 2 , Y和R 3 具有说明书中给出的含义以及药学上可接受的衍生物（包括前药），这些化合物和衍生物可用作竞争性胰蛋白酶样蛋白酶抑制剂，如凝血酶，因此，特别是用于需要抑制凝血酶的情况（例如血栓形成）或作为抗凝剂。
• Benzene, Pyridine, and Pyridazine Derivatives
  申请人：Huang Kenneth He

  公开号：US20080119457A1

  公开（公告）日：2008-05-22

  Disclosed are compounds and pharmaceutically acceptable salts of Formula I wherein A, Q 1 , Q 2 , Q 3 , R 31 , and R 41 are as defined herein. Compounds of Formula I are useful in the treatment of diseases and/or conditions related to cell proliferation, such as cancer, inflammation, arthritis, angiogenesis, or the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.

  公开了公式I的化合物和药用盐，其中A、Q1、Q2、Q3、R31和R41如本文所定义。公式I的化合物在治疗与细胞增殖相关的疾病和/或病况方面具有用途，如癌症、炎症、关节炎、血管生成等。还公开了包括本发明化合物的药物组合物以及使用这些化合物治疗上述病况的方法。
• Inhibitors of prenyl-protein transferase
  申请人：Merck & Co., Inc.

  公开号：US06441017B1

  公开（公告）日：2002-08-27

  The present invention is directed to macrocyclic compounds which inhibit prenyl-protein transferase (FTase) and the prenylation of the oncogene protein Ras. The invention is further directed to chemothera-peutic compositions containing the compounds of this invention and methods for inhibiting prenyl-protein transferase and the prenylation of the oncogene protein Ras.

  本发明涉及抑制萜基-蛋白转移酶（FTase）和致癌基因蛋白Ras的大环化合物。该发明还涉及含有本发明化合物的化疗组合物以及抑制萜基-蛋白转移酶和致癌基因蛋白Ras的方法。
• [EN] COMPOUNDS<br/>[FR] COMPOSÉS
  申请人：CTXT PTY LTD

  公开号：WO2019243491A1

  公开（公告）日：2019-12-26

  A compound of formula (I), or a pharmaceutical salt thereof.

  式(I)的化合物，或其药用盐。